These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30471002)

  • 1. Tapentadol Prolonged Release: A Review in Pain Management.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1805-1816. PubMed ID: 30471002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study.
    Baron R; Martin-Mola E; Müller M; Dubois C; Falke D; Steigerwald I
    Pain Pract; 2015 Jun; 15(5):455-70. PubMed ID: 24738609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol prolonged release and the long-term management of chronic musculoskeletal pain in the elderly - focus on anxiety, depression, cognitive status and life quality: the TaPE study.
    Tarsitano A; Cortese M; Barile M; Scarpelli P
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):35-39. PubMed ID: 31755081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release.
    Mateos RG; Bernal DS; Morera LMT; Ferri CM; Escobar AE
    Pain Physician; 2021 Jan; 24(1):E75-E85. PubMed ID: 33400440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
    Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
    Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
    Bagaphou TC; Cerotto V; Gori F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
    Baron R; Kern U; Müller M; Dubois C; Falke D; Steigerwald I
    Pain Pract; 2015 Jun; 15(5):471-86. PubMed ID: 24750558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study.
    Aurilio C
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):40-44. PubMed ID: 31755085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study.
    Visconti C; Mastroluca A; Varano L; Del Gaudio A
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):27-34. PubMed ID: 31755082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of tapentadol prolonged release during rehabilitation: a prospective, observational study.
    Orfei M; Milia P; Caserio M; Bagaphou TC
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):21-26. PubMed ID: 31755077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
    Schwittay A; Sohns M; Heckes B; Elling C
    Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
    Agbalaka A; Schwenke K; Litzenburger B
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
    Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
    Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
    Kern KU; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study.
    Finco G; Mura P; Musu M; Deidda C; Saba M; Demelas I; Evangelista M; Sardo S
    Minerva Med; 2018 Aug; 109(4):259-265. PubMed ID: 29947490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.